New approach aims to tame tough blood cancer with fewer side effects
NCT ID NCT07227311
Summary
This study is for adults whose multiple myeloma, a type of blood cancer, has returned or stopped responding to prior treatments. The main goal is to see if giving the drug belantamab mafodotin less frequently, in combination with other standard cancer drugs, can still effectively control the cancer while potentially reducing side effects, particularly those affecting the eyes. Researchers will measure how well the cancer responds and monitor the safety of this treatment approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.